ClinicalTrials.gg
RecruitingNCT07463209INSIDE-CGMUpdated Oct 5, 2026

Integrating New Skills Into Diabetes Education With CGM

An interventional study of Three-stage CGM integration program and One-time clinic-based CGM training in Insulin Dependent Diabetes, Diabetes (DM) and Diabetes (Insulin-requiring, Type 1 or Type 2), sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 5, 2026Primary completion movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
244th of 1,242
144 · median 40
Started
2026
with 61 others
No phase
614 of 1,458
99 open now
Primary completion
2028-03
later than 187 of 256 live
Registered
1,423rd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 244th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 614 with no phase, reaches primary completion later than 187 of the 256 other live ones, and was the 1,423rd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

184 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin. This study will learn if a three-stage CGM integration program ("intervention") that includes sessions focused on CGM technology skills, data skills, and lifestyle skills impacts CGM wear-time, glycemic metrics, and participant-reported outcomes, compared to two standard CGM training approaches ("comparators").

Following a screening visit and baseline data collection, participants will be randomized to either the intervention or one of the two comparator arms for 6 weeks. The intervention involves three educational sessions over 4 weeks. The first session will be in-person and subsequent sessions will be virtual. Participants in the intervention may receive 1-2 additional individualized training sessions to review CGM skills. The first comparator (Comparator 1) will receive a one-time clinic-based CGM training. The second comparator (Comparator 2) will be provided with a comprehensive informational pamphlet about CGM. All participants will complete outcomes data collection at 6 weeks.

The study will also explore participant experiences through a series of semi-structured interviews with a subset of purposively selected participants and their care partners to identify opportunities for scaling the intervention to a broader population. An extension phase of the study will evaluate long-term CGM use and associated outcomes 3- and 6-months post-intervention.

Lastly, we will run an additional small sub-study where consented care partners of participants will attend the intervention or comparator sessions alongside the study participant and provide care partner-specific data.

Read the detailed description

This study will assess the preliminary effectiveness of a continuous glucose monitor (CGM) integration program ("intervention") in a 6-week randomized pilot study among 144 older adults with diabetes using insulin at least once daily. The CGM integration program (48 participants) will be compared to two versions of usual care: 1) one-time clinic-based CGM training (Comparator 1; 48 participants) and 2) self-directed CGM training (Comparator 2; 48 participants). Following a screening visit and baseline data collection, participants will be randomized to one of the three groups in a 1:1:1 ratio by computer-generated sequence. All participants will be provided with 6-week supply of unblinded CGM sensors.

Participants who are randomized to the intervention group will attend three closed group sessions over 4 weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be held virtually and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be held virtually and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.

Participants randomized to the one-time clinic-based CGM training group (Comparator 1) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Participants randomized to the self-directed CGM training (Comparator 2) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.

At the end of the 6-week trial, all participants will provide primary endpoint data related to continuous wear-time. In addition, secondary patient-reported outcomes and glycemic metrics will be assessed, including use of the CGM device at 6 weeks. We will conduct semi-structured interviews with a subset of purposively sampled participants (up to 20) and their care partners (up to 10) after their final endpoint visit to probe effective aspects of the intervention, challenges, struggles, and needs that were not addressed by the intervention, and strategies to improve the accessibility, acceptability, and effectiveness of the intervention for future older adults.

We will conduct an extension study in which we evaluate the following metrics at 3- and 6-months post-intervention: 1) CGM prescribing patterns post-study, including the proportion of participants with a CGM order at 3 and 6 months after study endpoint; 2) Clinical and patient-reported outcomes, such as glycemic indicators, severe hypoglycemia, device satisfaction (if applicable), barriers to sustained CGM access, integration of CGM into care and self-management, and unmet needs; 3) provider documentation of clinical rationale, perceived benefits, and barriers to CGM use across diverse care settings (internal medicine, family medicine, geriatrics, endocrinology).

Lastly, this study will involve a care partner sub-study. The aim of the care partner sub-study is to understand how the intervention improves or changes the knowledge and attitudes around CGM and diabetes management in care partners of older adults with diabetes. Consented care partners will be invited to attend any session their partner participant is assigned to. Care partners will be asked to complete care partner-specific questionnaires at baseline, at the end of the 6-week trial, and at 3- and 6-months post-intervention.

03

Conditions studied

  • Insulin Dependent Diabetes
  • Diabetes (DM)
  • Diabetes (Insulin-requiring, Type 1 or Type 2)
  • Diabetes Education
  • Diabetes Care
  • Type 1 Diabetes (T1D)
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Continuous Glucose Monitor
  • Diabetes
  • Insulin Dependent
  • Older Adults (65 years and older)
  • CGM
  • Diabetes Education
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participant Inclusion Criteria:

  • Adults 65 years and older at time of consent
  • Actively receiving care at a UNC Health or UNC Physicians Network clinic (defined as 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics within the past 365 days). Locality for care is defined as receiving care within a 90-mile radius of UNC Main Hospital on Manning Drive in Chapel Hill, NC.
  • Using any insulin at least once daily
  • No continuous glucose monitor (CGM) use within the previous 365 days
  • Willing to use a smartphone to access glucose readings using CGM phone app. Willing to use a loaner smartphone or receiver if personal smartphone is not compatible with CGM phone app.
  • Fluent in English

Participant Exclusion Criteria:

  • Clinical diagnosis of dementia, assessed through chart review and self-report on screening visit (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable)
  • Currently receiving dialysis, assessed through chart review and self-report on screening visit
  • Extreme visual or hearing impairment that would impair ability to use real-time CGM or attend and participate in an in-person or virtual group intervention session, assessed at screening visit
  • The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with of \<1 year, assessed at screening visit
  • Unavailable for 6-week study duration (such as planned surgery or procedure, planned vacation, etc.) or unwilling to comply with study procedures
  • Not fluent in English
  • Unable to consent to recording of sessions

Care Partner Inclusion Criteria:

  • Live in the same household as the study participant
  • Age 18 years or older
  • Fluent in English
  • Be willing to attend sessions alongside the study participant and learn how they can better support their partner participant to manage diabetes
  • Consent to recording of sessions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Intervention

    Three-stage CGM integration program

    Behavioral: Three-stage CGM integration program

  • Active comparator
    Comparator A

    One-time clinic-based CGM training

    Behavioral: One-time clinic-based CGM training

  • Active comparator
    Comparator B

    Self-directed CGM training

    Behavioral: Self-directed CGM training

Interventions

  • BehavioralThree-stage CGM integration program

    Participants (and their consented care partner, if applicable) who are randomized to the intervention group will attend three closed group sessions over four weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be hybrid and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be hybrid and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.

  • BehavioralOne-time clinic-based CGM training

    Participants (and their consented care partner, if applicable) randomized to the one-time clinic-based CGM training group (Comparator A) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.

  • BehavioralSelf-directed CGM training

    Participants randomized to the self-directed CGM training (Comparator B) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Consented care partners will not be directly involved, as there is no session visit to attend.

06

What researchers measure

Primary outcomes

  1. CGM Wear Time

    CGM wear time will be calculated as the percentage of time that the sensor is in use and providing data, relative to the total time it could have been worn, with a total of 6-weeks of total possible wear during the active intervention period.

    Time frame: Over 6 Weeks

Secondary outcomes

  1. CGM Use at 6 Weeks

    CGM use will be determined as a yes/no binary response as to whether the study participant is wearing a CGM at the 6-week endpoint of the study intervention.

    Time frame: Week 6

  2. Change in Core Diabetes Distress using the Type 1 Diabetes Distress Assessment System (T1-DDAS) Core Score

    The T1-DDAS will be administered to participants with Type 1 Diabetes. Self-reported core diabetes distress will be measured using the 30-item Type 1 Diabetes Distress Assessment System (T1-DDAS) Core Score. The scale yields a core score that is the average of all core questions (first 8 items) responses rated on a 5-point Likert scale for all 8 items, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher distress. A score \>= 2.0 is considered clinically significant diabetes distress.

    Time frame: Baseline, Week 6, Month 3, Month 6

  3. Change in Core Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score

    The T2-DDAS will be administered to participants with Type 2 Diabetes. Self-reported core diabetes distress will be measured using the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score. The scale yields a core score that is the average of all core questions (first 8 items) responses rated on a 5-point Likert scale for all 8 items, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher distress. A score \>= 2.0 is considered clinically significant diabetes distress.

    Time frame: Baseline, Week 6, Month 3, Month 6

  4. Change in Sources of Diabetes Distress using the Type 1 Diabetes Distress Assessment System (T1-DDAS) Source Score

    The T1-DDAS will be administered to participants with Type 1 Diabetes. Self-reported sources of diabetes distress will be measured using the 30-item Type 1 Diabetes Distress Assessment System (T1-DDAS) source scale. Responses are rated on a 5-point Likert scale, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher impact that the source is likely to have in contributing to diabetes distress.

    Time frame: Baseline, Week 6, Month 3, Month 6

  5. Change in Sources of Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Source Score

    The T2-DDAS will be administered to participants with Type 2 Diabetes. Self-reported sources of diabetes distress will be measured using the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) source scale. Responses are rated on a 5-point Likert scale, ranging from 1 (not a problem) to 5 (a very serious problem). Higher scores indicate higher impact that the source is likely to have in contributing to diabetes distress.

    Time frame: Baseline, Week 6, Month 3, Month 6

  6. Change in Impact of Diabetes Quality of Life-Brief Clinical Inventory (DQOL) Score

    Self-reported DQOL 15-item survey will be measured. Responses are rated on 5-point Likert scale. 7 questions ask about the frequency of negative impacts of diabetes or diabetes treatment and are scored from 1 (Never) to 5 (All the Time). 8 questions ask about satisfaction with treatment and quality of life and are scored from 1 (Very Satisfied) to 5 (Very Dissatisfied). Scoring is done by adding the numeric responses to the 15 questions, and can range from 15-75, with a higher score indicating a higher problem frequency or more dissatisfaction.

    Time frame: Baseline, Week 6, Month 3, Month 6

  7. Change in Self Care Inventory-Revised Version (SCI-R) Score

    Self-reported SCI-R 15-item survey will be measured. Responses are rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). For scoring, items are averaged and converted to a 0- to 100-point scale. Items that are not rated (or not applicable) are not included in the scoring. Higher scores indicate a better self-care.

    Time frame: Baseline, Week 6

  8. Change in Glucose Monitoring System Satisfaction Survey (GMSS) Type 1 Diabetes version Score

    The GMSS Type 1 Diabetes version will only be administered to participants with Type 1 Diabetes. Self-reported glucose monitoring system satisfaction will be measured using the 15-item questionnaire. Responses are rated on a 5-point Likert scale with responses ranging from 1 (strongly disagree) to 5 (strongly agree). Scoring is done by calculating the mean score across responses. Certain items need to be reverse coded. A higher total score indicates greater satisfaction.

    Time frame: Baseline, Week 6

  9. Change in Glucose Monitoring System Satisfaction Survey (GMSS) Type 2 Diabetes version Score

    The GMSS Type 2 Diabetes version will only be administered to participants with Type 2 Diabetes. Self-reported glucose monitoring system satisfaction will be measured using the 15-item questionnaire. Responses are rated on a 5-point Likert scale with responses ranging from 1 (strongly disagree) to 5 (strongly agree). Scoring is done by calculating the mean score across responses. Certain items need to be reverse coded. A higher total score indicates greater satisfaction.

    Time frame: Baseline, Week 6

  10. Change in Benefits of CGM (BenCGM) Score

    Self-reported BenCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items using a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A higher mean score indicates higher perceived benefit of continuous glucose monitor (CGM).

    Time frame: Baseline, Week 2, Week 4, Week 6, Month 3, Month 6

  11. Change in Burdens of CGM (BurCGM) Score

    Self-reported BurCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items based on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A higher mean score indicates higher perceived barriers of continuous glucose monitor (CGM).

    Time frame: Baseline, Week 2, Week 4, Week 6, Month 3, Month 6

  12. Change in Opinions and Beliefs about CGM Technology [Investigator-written]

    Investigator-written items will assess participant opinions and beliefs about using CGM technology, with Likert scale responses to statements ranging from 1 (strongly disagree) to 6 (strongly agree). Change across each item will be calculated at key intervention milestones and used to understand efficacy of the intervention, with higher scores equating to higher confidence in CGM use and application.

    Time frame: Week 2, Week 4, Week 6, Month 3, Month 6

  13. Change in sleep quality affected by CGM [Investigator-written]

    Investigator-written items to assess impact of CGM on sleep. Responses about sleep quality and impact will be ranked and assessed individually per item, with higher ranked responses indicating worsened impacts on sleep.

    Time frame: Week 2, Week 4, Week 6, Month 3, Month 6

  14. Change in quality of life affected by CGM [Investigator-written]

    Investigator-written open-ended questions will explore impacts of participant CGM use on daily life. Responses will be thematically coded with standard qualitative data analysis methods.

    Time frame: Week 2, Week 4, Week 6, Month 3, Month 6

  15. Change in CGM satisfaction (CGM-SAT) Score

    Impact of CGM intervention on CGM satisfaction will be reported at endpoint after the intervention (week 6) and at month 3 and month 6 if participant is using personal CGM at month 3 and month 6. Self-reported CGM-SAT 44-item survey will be measured. Responses are on a 5-point Likert scale with responses ranges from 1 (agree strongly) to 5 (disagree strongly). After reverse scoring some items, the mean is calculated with higher mean scores reflecting greater satisfaction with CGM. This scale also includes two open-ended questions that will be evaluated using qualitative research methods.

    Time frame: Week 6, Month 3, Month 6

  16. Change in Hypoglycemia Fear (Hypoglycemia Fear Survey; Worry Subscale, HFS-II W) Score

    Self-reported HFS-II W 18-item survey will be measured. The scale is a 5-point Likert scale with responses ranging from 0 (never) to 4 (almost always). A score of 3 or higher on any of the 18 items indicates fear of hypoglycemia. Higher average scores indicate higher fear of hypoglycemia.

    Time frame: Baseline, Week 6

  17. Change in Clarke Score (Hypoglycemia Unawareness)

    Self-reported Clarke Score 8-item survey will be measured. Each answer correlates with a rating of A (aware) or R (reduced). 4 or more R responses suggest reduced hypoglycemia awareness. 3 responses suggest indeterminant hypoglycemia awareness. 2 or fewer R responses suggest hypoglycemia awareness.

    Time frame: Baseline, Week 6

  18. Change in Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1) Score

    Likert-type scale questions ranging from 1 (extremely unlikely) to 7 (extremely likely) for likelihood that each of the items would keep you from practicing regular physical activity during the next 6 months. Responses across 12-items are averaged, with lower average scores indicating a low level of perceived barriers to physical activity.

    Time frame: Baseline, Week 6

  19. Change in Healthy Eating Index (HEI) Score based on average intake across two 24-hour recalls

    Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24)) per timepoint. Healthy Eating Index (HEI) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating from a select list of healthy food categories. The scores range from 0 to 100. An ideal overall Healthy Eating Index score of 100 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).

    Time frame: Baseline, Week 6

  20. Change in carbohydrate intake based on average intake across two 24-hour recalls

    Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24)) per timepoint. Carbohydrate intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.

    Time frame: Baseline, Week 6

  21. Change in protein intake based on average intake across two 24-hour recalls

    Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool; ASA24) per timepoint. Protein intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.

    Time frame: Baseline, Week 6

  22. Change in fat intake based on average intake across two 24-hour recalls

    Participants will be contacted to self-administer two 24-hour dietary recalls (Automated Self-Administered 24-Hour Dietary Assessment Tool; ASA24) per timepoint. Fat intake (% of total kcal) will be calculated based on the recall responses averaged across both recalls delivered at each timepoint.

    Time frame: Baseline, Week 6

  23. Change in General Self-Efficacy Scale (GSE) Score

    Self-reported General Self-Efficacy Scale (GSE) will be measured. Participants will be Likert-type scale questions ranging from Not at all true (1), Hardly true (2), Moderately true (3), Exactly true (4). The total score is calculated by finding the sum of all items. For the GSE, the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.

    Time frame: Baseline, Week 6

  24. Change in Hemoglobin A1c (HbA1c)

    HbA1c (%) reflects average glucose over the past 2-3 months. Value will be assessed by standardized laboratory assay at baseline and Month 3.

    Time frame: Baseline, Month 3

  25. Change in Percentage of Time in Range (TIR)

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Baseline, Week 6

  26. Change in Percentage of Time Below Range (TBR)

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Baseline, Week 6

  27. Change in Percentage of Time Above Range (TAR)

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Baseline, Week 6

  28. Change in Percentage of Glycemic Variability

    When using the blinded continuous glucose monitors (CGM), glycemic variability will be assessed using the coefficient of variation (%CV) using 7-14 days of retrospective data at each time-point.

    Time frame: Baseline, Week 6

  29. Change in Percentage of Time in Range (TIR)

    If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Month 3, Month 6

  30. Change in Percentage of Time Below Range (TBR)

    If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Month 3, Month 6

  31. Change in Percentage of Time Above Range (TAR)

    If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). The percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point.

    Time frame: Month 3, Month 6

  32. Change in Percentage of Glycemic Variability

    If participant is wearing a personal/unblinded CGM, data will be collected and assessed for change from baseline and endpoint (week 6). Glycemic variability will be assessed using the coefficient of variation (%CV) using 7-14 days of retrospective data at each time-point.

    Time frame: Month 3, Month 6

  33. Change in care partner Opinions and Beliefs about CGM Technology [Investigator-written]

    Investigator-written items will assess opinions and beliefs of care partners about participant's use of CGM technology, with Likert scale responses to statements ranging from 1 (strongly disagree) to 6 (strongly agree). Change across each item will be calculated at key intervention milestones and used to understand efficacy of the intervention, with higher scores equating to higher confidence in CGM use and application.

    Time frame: Baseline, Week 6, Month 3, Month 6

  34. Change in care partner sleep quality affected by CGM [Investigator-written]

    Investigator-written items to assess impact of participant CGM use on care partner's sleep. Responses about sleep quality and impact will be ranked and assessed individually per item, with higher ranked responses indicating worsened impacts on sleep.

    Time frame: Baseline, Week 6, Month 3, Month 6

  35. Change in care partner quality of life affected by CGM [Investigator-written]

    Investigator-written open-ended questions will explore impacts of participant's CGM use on care partner's daily life. Responses will be thematically coded with standard qualitative data analysis methods.

    Time frame: Baseline, Week 6, Month 3, Month 6

  36. Change in Care Partner Diabetes Distress (Partner DDS) Score

    Care partners of participants will be offered to complete the 21-item Partner Diabetes Distress (Partner DDS) questionnaire. The survey yields a mean score based on a 4-point Likert scale with responses ranging from 0 (not at all) to 4 (a great deal). Total score is calculated as the mean of the 21 items. Mean item score of 0-1.9 is considered little or no distress, between 2-2.9 is considered moderate distress, and \>=3 is considered high distress.

    Time frame: Baseline, Week 6, Month 3, Month 6

  37. Change in Care Partner Hypoglycemia Confidence Scale (Partner-HCS) Score

    Care partners of participants will be offered to complete the 12-item Partner Hypoglycemia Confidence Scale (Partner-HCS). The survey yields a mean score based on a 4-point Likert scale with responses ranging from 1 (not confident at all) to 4 (very confident). Total score is calculated as the mean of the 12 items. Higher mean score reflects higher partner hypoglycemia confidence and lower mean score reflects lower partner hypoglycemia confidence.

    Time frame: Baseline, Week 6, Month 3, Month 6

  38. Change in DAWN Family Experience of Patient Involvement (DFEPI) Score

    Care partners of participants will be offered to complete the 4-item DAWN Family Experience of Patient Involvement (DFEPI). Two questions use a Likert scale with responses ranging from 1 (never) to 5 (always) to assess communication of support needs. Higher composite scores indicate a higher level of communication received about needs for support. Two questions use a Likert scale with responses ranging from 1 (much less involved) to 5 (much more involved) to assess preferred level of involvement of family member. Higher composite scores indicate a care partner's higher desire for involvement in the participant's diabetes care.

    Time frame: Baseline, Week 6, Month 3, Month 6

  39. Change in DAWN Impact of Diabetes Profile - Family Members (DIDP-FM) Score

    Care partners of participants will be offered to complete the 7-item DAWN Impact of Diabetes Profile - Family Members (DIDP-FM). The survey yields a composite score based on a 7-point Likert scale with responses ranging from 1 (very negative impact) to 7 (very positive impact). N/A responses (8) are treated as missing. A composite scale score can be derived by taking the sum of items divided by the number of complete responses (i.e. not missing or N/A). Lower scale scores indicate greater negative impact and higher scale scores indicate greater positive impact of diabetes on a family member's life.

    Time frame: Baseline, Week 6, Month 3, Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 6 to 18 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Time frame: Beginning 6 and continuing for 18 months following publication

Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 19 months is close to that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2028 → Mar 2028, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 11, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Mar 2028was Feb 2028
CompletionEst.
Jun 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2028→Mar 2028
Oct 5, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedWilling to use a smartphone to access glucose readings using CGM phone app. Willing to use a loaner smartphone or receiver if personal smartphone is not compatible with CGM phone app.
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Feb 2028→Mar 2028
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedWilling to use a smartphone to access glucose readings using CGM phone app. Willing to use a loaner smartphone or receiver if personal smartphone is not compatible with CGM phone app.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07463209
Collaborators
American Diabetes Association
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Aug 11, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Marcy Menard, MS, RD, LDN, CDCES
Contact
mmenard@unc.edu
919-843-9977
Angela Fruik, MPH, RD, LDN
Contact
angela.fruik@unc.edu
919-962-6348
Anna Kahkoska, MD, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion